MedPath

Prognostic Value of BNP in MCS - a 25 Year Follow up Study

Recruiting
Conditions
Heart Failure
Durable Mechanical Support Device
Left Ventricular Assist Device
Prognosis
Registration Number
NCT04377854
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy.

Patients will be followed up for 25 years after inclusion.

Detailed Description

All patients referred for advanced HF treatment at the Dept of Cardiology at Rigshospitalet.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
  • Age>18 years
Exclusion Criteria
  • No consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Dead25 years from inclusion

Dead after inclusion in study

Alive25 years from inclusion
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rigshospitalet

🇩🇰

Copenhagen, DK, Denmark

Rigshospitalet
🇩🇰Copenhagen, DK, Denmark
Kiran Mirza, MD
Contact
+4535451442
kmir0003@regionh.dk
Finn Gustafsson, MD,PhD,DMSc.
Contact
+4535459743
Finn.Gustafsson@regionh.dk

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.